MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Danaher Corp

Открыт

СекторЗдравоохранение

196.33 0.59

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

192.84

Макс.

197.06

Ключевые показатели

By Trading Economics

Доход

268M

1.1B

Продажи

738M

6.5B

P/E

Средняя по отрасли

34.964

57.333

Прибыль на акцию

2.14

Дивидендная доходность

0.69

Рентабельность продаж

16.611

Сотрудники

61,000

EBITDA

-230M

1.4B

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+22.75% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.69%

2.63%

Следующий отчет о доходах

22 июл. 2025 г.

Дата следующей выплаты дивидендов

25 апр. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-29B

134B

Предыдущая цена открытия

195.74

Предыдущая цена закрытия

196.33

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Danaher Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

22 апр. 2025 г., 10:34 UTC

Отчет

Danaher 1Q Results Decline But Top Estimates

5 февр. 2025 г., 12:54 UTC

Отчет

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 янв. 2025 г., 11:44 UTC

Отчет

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 окт. 2024 г., 10:35 UTC

Отчет

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

22 апр. 2025 г., 10:02 UTC

Отчет

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 апр. 2025 г., 10:02 UTC

Отчет

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 апр. 2025 г., 10:02 UTC

Отчет

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 апр. 2025 г., 10:01 UTC

Отчет

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 апр. 2025 г., 10:01 UTC

Отчет

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 апр. 2025 г., 10:00 UTC

Отчет

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 апр. 2025 г., 10:00 UTC

Отчет

Danaher 1Q Adj EPS $1.88 >DHR

22 апр. 2025 г., 10:00 UTC

Отчет

Danaher 1Q EPS $1.32 >DHR

22 апр. 2025 г., 10:00 UTC

Отчет

Danaher 1Q Sales $5.74B >DHR

22 апр. 2025 г., 10:00 UTC

Отчет

Danaher 1Q Net $954M >DHR

29 янв. 2025 г., 15:25 UTC

Обсуждения рынка
Отчет

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 янв. 2025 г., 13:56 UTC

Главные новости
Отчет

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 янв. 2025 г., 11:08 UTC

Отчет

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 янв. 2025 г., 11:07 UTC

Отчет

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 янв. 2025 г., 11:07 UTC

Отчет

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 янв. 2025 г., 11:02 UTC

Отчет

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 янв. 2025 г., 11:01 UTC

Отчет

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 янв. 2025 г., 11:01 UTC

Отчет

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 янв. 2025 г., 11:00 UTC

Отчет

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 янв. 2025 г., 11:00 UTC

Отчет

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 янв. 2025 г., 11:00 UTC

Отчет

Danaher 4Q Net $1.09B >DHR

29 янв. 2025 г., 11:00 UTC

Отчет

Danaher 4Q EPS $1.49 >DHR

29 янв. 2025 г., 11:00 UTC

Отчет

Danaher 4Q Adj EPS $2.14 >DHR

29 янв. 2025 г., 11:00 UTC

Отчет

Danaher 4Q Sales $6.5B >DHR

22 окт. 2024 г., 10:02 UTC

Отчет

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 окт. 2024 г., 10:02 UTC

Отчет

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Сравнение c конкурентами

Изменение цены

Danaher Corp Прогноз

Целевая цена

By TipRanks

22.75% рост

Прогноз на 12 месяцев

Средняя 241.2 USD  22.75%

Максимум 265 USD

Минимум 210 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Danaher Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

18 ratings

15

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

190.1 / 205.11Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.